Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

By sjmartinez • January 25, 2025

Krishnan S, Srivastava PK, Attaluri J, Nayeri R, Chatterjee D, Patel J, Nsair A, Budoff M, Nayeri A. Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence. J Cardiovasc Dev Dis. 2025 Jan 7;12(1):19. doi: 10.3390/jcdd12010019. PMID: 39852297; PMCID: PMC11766028.

Tags: Cardiology/Epi, GIP GLP-1 receptor agonist, Harbor UCLA, Hematology/Oncology, Metabolic syndrome, Obesity, Publications, semaglutide, tirzepatide, Veterans Administration, weight loss

Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome

Zhang C, Sarkar A, Wong E, Vaseghi M, Wang JJ. Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome.[...]

Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis

Repetti GG, Abel ED, Tontonoz P, Sallam T. Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis. Circ Res.[...]

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool

Jeanjean P, Swaidan A, Tse C, Kwock S, Fajnorova I, Dove R, Azrour IC, Taylor S, Comin-Anduix B, Nathanson DA, Carlucci G, Calais J, Czernin[...]